Breast Cancer: Update Bulletin #3
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA approval of Lynparza (olaparib; AstraZeneca) for patients with metastatic BC with BRCA gene mutation; Pfizer’s talazoparib EMBRACA Phase III data in patients with advanced or metastatic BC; as well as Syndax Pharmaceuticals announcing a collaboration with Genentech for a Phase Ib/II trial evaluating the combination of entinostat with Tecentriq (atezolizumab) in patients with second-line HR+/HER2- metastatic BC.
Business Questions:
Business Questions:
- How do KOLs view Lynparza’s approval?
- What do KOLs consider Lynparza’s advantages/disadvantages?
- According to KOLs, how will Lynparza be positioned?
- How does talazoparib’s safety/efficacy compare to Lynparza?
- Does talazoparib have any advantages over Lynparza?
- What do KOLs think of combining entinostat with Tecentriq (atezolizumab)?
- Which entinostat combination trial holds the most promise? Why?
More Publications
Breast Cancer: Update Bulletin [March 2016]
US$ 995.00
March 2016
-
Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]
US$ 995.00
January 2016
-
Prostate Cancer: Update Bulletin #2 [April 2018]
US$ 1,095.00
March 2018
-
Breast Cancer [2017]: Bulletin #1
US$ 1,045.00
July 2017
-
Bladder Cancer: Update Bulletin #2 [February 2018]
US$ 1,095.00
January 2018
-
